Bioelectronic technology company electroCore has completed the acquisition of neurotechnology solution provider NeuroMetrix including its Quell platform.

Last December, electroCore signed a definitive agreement to acquire NeuroMetrix (Nuro).

NeuroMetrix’s Quell platform is an app and cloud-enabled wearable neuromodulation solution intended to treat fibromyalgia symptoms via Quell Fibromyalgia and chronic pain through Quell 2.0.

The Quell Fibromyalgia device has received authorisation from the Food and Drug Administration (FDA) and is covered by 27 US patents.

It employs a custom microchip to deliver nerve stimulation in a compact form.

NeuroMetrix’s portfolio also includes another product, DPNCheck, a point-of-care test intended for peripheral neuropathy.

DPNCheck is excluded from this deal.

Last year in December, electroCore had stated in its press release that DPNCheck is expected to be divested by NeuroMetrix before the consummation of this deal.

As per the terms of the merger, which was approved by NeuroMetrix's shareholders in March 2025, each share of NeuroMetrix common stock, outstanding immediately before the transaction closure, was converted into the right to receive a cash payment of $4.49 per share and one contingent value right (CVR).

These CVRs provide holders with potential cash payments based on sales milestones from the Quell business and future proceeds from the sale of DPNCheck business, contingent to the terms defined in the CVR agreement dated 1 May 2025.

With the acquisition, NeuroMetrix became an indirect wholly-owned electroCore subsidiary.

The acquisition of NeuroMetrix's Quell Fibromyalgia Solution enhances electroCore's range of non-invasive bioelectronic therapies, broadens its commercial presence—especially within the VA Hospital System—and is anticipated to significantly expand its target market for addressing chronic pain and wellness issues.

electroCore CEO Dan Goldberger said: “With this transaction now closed, we are well-positioned to immediately leverage our established distribution channels, particularly within the VA Hospital System, to accelerate adoption of the Quell Fibromyalgia solution.

“This addition meaningfully expands our addressable market and diversifies our portfolio of non-pharmaceutical, non-invasive nerve stimulation offerings, strengthening electroCore’s position as a leading publicly traded bioelectronic technology platform focused on wellness and chronic pain management.”

In January 2023, NeuroMetrix launched its DPNCheck 2.0 device commercially for peripheral neuropathy detection.

Story Continues

"electroCore completes acquisition of neurotechnology solution provider NeuroMetrix" was originally created and published by Medical Device Network, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

View Comments